Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PamGene's microarray diagnostics shows promise:

This article was originally published in Clinica

Executive Summary

PamGene International, of `s-Hertogenbosch, the Netherlands, says that preliminary results from research to develop rapid microarray diagnostics for tuberculosis identification and drug resistance monitoring are promising. The firm is developing the microarray platform, PamChip, with KIT Biomedical Research, the business unit of KIT at Amsterdam's Royal Tropical Institute. It claims that according to its research, the technology could represent the "world's fastest microarray". The rapid technology, it says, was achieved by pulsing the target through a porous substrate of different probes for mycobacteria species identification.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts